FDA sets deadline for Ascendis Pharma drug decision

Ascendis Pharma’s marketing authorization application for its Transcon PTH candidate must be responded to by April 2023.

Photo: Kevin Grønnemann

Danish biotech firm Ascendis Pharma now knows when it can expect a response to its application for Transcon PTH (palopegteriparatide), which it submitted to the US Food and Drug Administration, FDA, in August.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs